A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
adult patients, \>=18 years of age;
locally advanced metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC);
\>=1 measurable tumor lesion;
ECOG performance status 0-1.
You may not be if
prior chemotherapy or treatment with another systemic anti-cancer agent;
evidence of CNS metastases;
history of grade 2 or higher hemoptysis;
evidence of tumor invading or abutting major blood vessels;
malignancies other than NSCLC within 5 years prior to randomization, other than adequately treated cancer in situ of cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS;
clinically significant cardiovascular disease;
current or recent use of aspirin (\>325mg/day) or full dose anticoagulants or thrombolytic agents for therapeutic purposes.
Clareo Health | A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
